Spruce Biosciences Q1 net loss $11.6M; cash $81.2M; CAHmelia-204 data expected Q3 2024

SPRUCE BIOSCIENCES, INC.

2024-Q1 EPS reported -$0.28 revenue$2,002,000

Cash and cash equivalents $81.2M as of March 31, 2024; expected to fund operations through end of 2025.
Net loss of $11.6M vs $12.8M in Q1 2023; R&D expenses $10.3M (down from $11.7M).
Collaboration revenue of $2.0M from Kaken Pharmaceutical agreement.
CAHmelia-203 analyses show higher GC dose and drug compliance correlate with larger A4 reductions.
Topline data from CAHmelia-204 (adult CAH) and interim dose-ranging from CAHptain-205 (pediatric) expected Q3 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

SPRUCE BIOSCIENCES, INC. reported financial results for first quarter ended March 31, 2024.

Period: first quarter ended March 31, 2024
Result: reported results

Exact text from the filing

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the first quarter ended March 31, 2024 and provided corporate updates.

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

SPRUCE BIOSCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0000950170-24-058635

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.